Article: Total Nutraceutical Solutions Enters Into Agreement With Model Biosystems to Test Proprietary Mushroom Compounds in Suppressing Alzeheimer's Disease.

STEVENSON, Wash. -- Total Nutraceutical Solutions, Inc. (TNS) (OTCBB:TNUS), announced today that the company has started evaluating several proprietary mushroom compounds for activity in controlling the development of Alzheimer's Disease (AD). TNS was informed by Model Biosystems, Inc. (MBS), San Clemente, CA, that a recent experiment in Drosophila melanogaster flies (Drosophila) showed that certain TNS proprietary mushrooms had unusual anti-inflammatory activity. MBS was of the opinion that TNS should evaluate these mushroom samples in a special MBS biologic model for Alzheimer's disease (AD). This proprietary AD model uses a genetic mutant of Drosophila that was ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!